Last reviewed · How we verify
Stop group
This drug works by inhibiting the renin-angiotensin system.
This drug works by inhibiting the renin-angiotensin system. Used for Hypertension, Heart failure.
At a glance
| Generic name | Stop group |
|---|---|
| Also known as | discontinue antiviral treatment, TNF-alpha antagonists withdrawal |
| Sponsor | Asan Medical Center |
| Drug class | Angiotensin receptor blocker |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
By blocking the action of angiotensin II, it reduces blood pressure and decreases the workload on the heart.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Dizziness
- Headache
- Cough
- Fatigue
- Nausea
Key clinical trials
- Rosacea and Ivermectin (PHASE2)
- The Impact of Equine-Assisted Therapy on Mental Health and Addictive Behaviors in Patients Receiving Addiction Treatment (NA)
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Bedside Bike Early Mobilization Program for Inpatients (NA)
- The Effect of the DASH Diet on Treatment Outcomes in Adults Diagnosed With Rheumatoid Arthritis (NA)
- Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer (PHASE2)
- A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events (NA)
- Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |